文拉法辛与氟西汀治疗抑郁症的疗效和安全性比较

摘要

Objective To investigate the clinical efficacy and safety of venlafaxine in the treatment of depression to provide the guidance for clinical drug use.Methods 38 patients with depression in our hospital from January 2011 to October 2012 were selected and randomly divided into the treatment group and the control group.The treatment group was treated with venlafaxine and the control group was given fluoxetine,for 8-week therapy.The Hamilton Rating Scale (HAMD) was adopted to evaluate the clinical efficacy of the two groups,and the Treatment Emergent Symptoms Scale (TESS) was adopted for evaluating the security during the treatment process.Results The total effective rate after treatment had no statistical difference between the two groups (P ＞ 0.05);the HAMD score in different treatment stages showed no statistical difference (P ＞ 0.05);but the HAMD scores before and after treatment had statistically significant differences in the two groups (P ＜ 0.05).The TESS scores difference between the two groups was not statistically significant (P ＞ 0.05).There was no significant difference in adverse reactions between the two groups(P ＞ 0.05).Conclusion Venlafaxine has definite clinical efficacy in the treatment of depression,significantly improves the patient's symptoms,with mild dverse reactions and good security,and is worth being widely used in clinical practice.%目的 探讨文拉法辛在抑郁症治疗中的临床疗效及安全性,为临床用药提供指导.方法 选择2011年1月至2012年10月医院收治的抑郁症患者38例,随机均分为两组.治疗组给予文拉法辛治疗,对照组给予氟西汀治疗,疗程8周,采用汉密尔顿抑郁量表(HAMD)评价两组的临床疗效,治疗过程中采用副反应量表(TESS)评价安全性.结果 两组患者治疗后总有效率差异无统计学意义(P＞0.05)；治疗中不同阶段的HAMD评分差异均无统计学意义(P＞0.05),治疗前与治疗后的HAMD评分差异均有统计学意义(P＜0.05),且TESS评分差异无统计学意义(P＞0.05),不良反应发生率也无明显差异(P＞0.05).结论 文拉法辛治疗抑郁症的临床疗效确切,能显著改善患者症状,且不良反应轻微,安全性好,值得临床推广.